

AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

- 1-25: (Canceled)
26. (New) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition comprising a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof.
27. (New) The method according to claim 26, wherein the pharmaceutical composition comprises recombinant streptokinase and a pharmacologically acceptable diluent carrier or excipient.
28. (New) The method according to claim 27, wherein the recombinant streptokinase has a concentration of 50,000 to 1,500,000 IU per gram of the pharmaceutical composition.
29. (New) The method according to claim 26, wherein the pharmaceutical composition further comprises ethylenediaminetetraacetic acid (EDTA).
30. (New) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium diclofenac.
31. (New) The method according to claim 26, wherein the pharmaceutical composition further comprises sodium salicylate.

Application Serial No.: 10/540,296

Filing Date: June 21, 2005

Docket: 976-28 PCT/US

Response to Non-Final Office Action issued October 26, 2007

Page 3 of 8

32. (New) The method according to claim 26, wherein the pharmaceutical composition is administered rectally.
33. (New) The method according to claim 32, wherein the pharmaceutical composition is a suppository.